We recently published a list of Jim Cramer Discusses TikTok Ban, President Trump & These 6 Stocks. In this article, we are ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Raymond James lowered the firm’s price target on Johnson & Johnson to $165 from $170 and keeps an Outperform rating on the shares.

Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.

The healthcare industry continues to evolve. Advancements in science and patients’ increasingly complex needs fuel this ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

“As the ownership group, our philosophy and feelings are that you guys own this team,” Kaufmann said. “It’s our job to make ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...

It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a wide economic moat. J&J holds a leadership role in diverse healthcare ...

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

WASHINGTON – House Republicans gave Mike Johnson the speaker's gavel on Friday – along with a warning. Nine GOP lawmakers at first either abstained from voting for Johnson or voted for a ...